Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New flowchart could reduce ICU time and pacemakers after TAVR

NCT ID NCT05417464

Knowledge-focused Sponsor: University Hospital, Montpellier Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested a simple flowchart to help doctors monitor and manage heart conduction problems after transcatheter aortic valve replacement (TAVR). The goal was to see if this approach could safely reduce the need for intensive care and permanent pacemakers. Researchers followed 250 patients and tracked serious conduction issues and pacemaker use.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Use of a flowchart for screening, monitoring, and management of conductive disorders
What this could lead to
If successful, this strategy could reduce the need for intensive care and pacemakers after TAVR, leading to shorter hospital stays and lower costs.
What could go wrong
This is a completed observational study, not a treatment trial. The flowchart is a management tool, so it cannot cure or directly treat heart disease. Results may not apply to all hospitals or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

250 people

The number who actually took part.

Started

Feb 2023

Finished

Oct 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Any patient who benefits from femoral TAVR regardless of the type of valve. * Age ≥ 18 years old. Exclusion Criteria: * Patients who require CICU monitoring for a reason other than conduction disorders * Patients with pacemaker or defibrillator * Pregnant or breastfeeding women * Patient refusing or unable to give consent: patient under guardianship or curator, mentally retarded, dementia, language barrier * Patient not affiliated with an SS scheme * Patient under judicial protection

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Valvular heart disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

aortic valve stenosis heart valve disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Valvular heart disease

Contacts and locations

Locations

  • University Hospital

    Montpellier, France, 34295, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.